Top Scientists Call On Global Health Agencies To Fund Innate Immunity Research As Additional Measure To Fight Pandemic Viruses
Global Experts Host Symposium and Agree that Innate Immunity May Be Effective, Globally Available Tool to Supplement Delay in Vaccine Availability and Distribution
News provided by
Share this article
Share this article
BALTIMORE, Jan. 8, 2021 /PRNewswire/ The Global Virus Network (GVN) and Washington University School of Medicine in St. Louis co-hosted a December 11, 2020 international symposium on innate immunity and COVID-19. Participants included nearly 950 registrants ranging from eminent virologists, researchers, health care professionals, health activists, government officials and representatives from the World Health Organization. GVN now joins top scientists from around the world to make an urgent appeal to funding agencies and regulatory authorities to prioritize innate immunity research as a means to fight pandemics.
BBV154 (intranasal Covid-19 vaccine), preclinical testing has been completed for toxicology, immunogenicity and challenge studies. These studies have been conducted in the USA and India. Phase I human clinical trials will commence during Feb-March 2021, an email reply from the city-based vaccine maker told P T I.
Phase I human clinical trials will be conducted in India, Bharat Biotech added.
The Phase-1 trials will be conducted in Saint Louis University s Vaccine and Treatment Evaluation Unit, the company sources said adding Bharat Biotech owns the rights to distribute the vaccine in all markets except USA, Japan and Europe.
Krishna Ella, Chairman of Bharat Biotech had earlier said the company is focusing on the intranasal vaccine as the existing vaccines require two dose intramuscular injections and a country like India needs 2.6 billion syringes and needles which may add up to pollution.
Bharat Biotech to begin Phase-1 trials of its intranasal vaccine for COVID-19 in February-March
Besides Covaxin, Bharat Biotech has been actively working on developing another vaccine, for which it tied up with Washington University School of Medicine in St Louis for the novel chimp-adenovirus (Chimpanzee adenovirus), a single dose in tranasal vaccine for COVID-19. PTI January 08, 2021 / 11:29 AM IST
Buoyed by the Emergency Use Authorisation approval from the Drug Controller General of India (DCGI)for its COVID-19 vaccine Covaxin, Bharat Biotech has said Phase-1 clinical trials of its new intranasal antidote for the killer virus will begin during February-March this year.
Bharat Biotech sends proposal to DCGI seeking approval for its nasal vaccine trials
Bharat Biotech sends proposal to DCGI seeking approval for its nasal vaccine trials
Bharat Biotech has sent a proposal to the Drugs Controller General of India (DCGI) to seek its approval for trials of a nasal vaccine against Covid-19.
advertisement
UPDATED: January 8, 2021 15:08 IST
Bharat Biotech has sent a proposal to DCGI to seek its approval for trials of a nasal vaccine against Covid-19.
Bharat Biotech has sent a proposal to the Drugs Controller General of India (DCGI) to seek its approval for trials of a nasal vaccine against Covid-19. Bharat Biotech has been working on a nasal vaccine apart from Covaxin, which has already been approved for emergency use in India.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CareDx Transplant Leadership Showcased at ASTS 2021
CareDx, Inc.January 8, 2021 GMT
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced it will be showcasing new transplant data at the upcoming 21st Annual American Society of Transplant Surgeons (ASTS) Digital Winter Symposium.
CareDx is sponsoring two symposia with key clinical leaders within transplantation, the speakers covering their real-world experiences using AlloSure to optimize care for their transplant patients, and highlighting novel data on the clinical utility of AlloSure. Of note, Dr. Jason Wellen will share initial data from the ADMIRAL study on AlloSure surveillance outcome